Cisplatin-Induced Giant Cells Formation Is Involved in Chemoresistance of Melanoma Cells

Melanoma is notoriously resistant to current cancer therapy. However, the chemoresistance mechanism of melanoma remains unclear. The present study unveiled that chemotherapy drug cisplatin induced the formation of giant cells, which exhibited enlargement in cell diameter and nucleus in mice and human melanoma cells. Giant cells were positive with melanoma maker S100 and cancer stem cell markers including ABCB5 and CD133 in vitro and in vivo. Moreover, giant cells retained the mitotic ability with expression of proliferation marker Ki-67 and exhibited multiple drug resistance to doxorubicin and actinomycin D. The mitochondria genesis/activities and cellular ATP level were significantly elevated in giant cells, implicating the demand for energy supply. Application of metabolic blockers such as sodium azide or 2-deoxy glucose abolished the cisplatin-induced giant cells formation and expression of cancer stemness markers. The present study unveils a novel chemoresistance mechanism of melanoma cells via size alteration and the anti-neoplastic strategy by targeting giant cells.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:21

Enthalten in:

International journal of molecular sciences - 21(2020), 21 vom: 24. Okt.

Sprache:

Englisch

Beteiligte Personen:

Weng, Chien-Hui [VerfasserIn]
Wu, Chieh-Shan [VerfasserIn]
Wu, Jian-Ching [VerfasserIn]
Kung, Mei-Lang [VerfasserIn]
Wu, Ming-Hsiu [VerfasserIn]
Tai, Ming-Hong [VerfasserIn]

Links:

Volltext

Themen:

8L70Q75FXE
968JJ8C9DV
9G2MP84A8W
ABCB5 protein, human
AC133 Antigen
ATP Binding Cassette Transporter, Subfamily B
Adenosine Triphosphate
Chemoresistance
Cisplatin
Deoxyglucose
Giant cell
Journal Article
Ki-67 Antigen
MKI67 protein, human
Melanoma
PROM1 protein, human
Q20Q21Q62J
S100 Proteins
Sodium Azide
Stemness

Anmerkungen:

Date Completed 02.03.2021

Date Revised 02.03.2021

published: Electronic

Citation Status MEDLINE

doi:

10.3390/ijms21217892

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM316829250